Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9632 |
High Similarity |
NPD6190 |
Approved |
0.8561 |
High Similarity |
NPD230 |
Phase 1 |
0.8264 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8065 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7899 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7892 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7834 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7818 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7805 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7794 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7771 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7758 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7733 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7716 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7716 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7716 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7707 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7643 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7639 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7622 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7622 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7616 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7613 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7609 |
Intermediate Similarity |
NPD9268 |
Approved |
0.7595 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.759 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7589 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7582 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7562 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7547 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7545 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7534 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7516 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7484 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7483 |
Intermediate Similarity |
NPD943 |
Approved |
0.747 |
Intermediate Similarity |
NPD7054 |
Approved |
0.747 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7468 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7452 |
Intermediate Similarity |
NPD3455 |
Phase 2 |
0.7425 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7425 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7421 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7421 |
Intermediate Similarity |
NPD37 |
Approved |
0.7405 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.74 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7396 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7391 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7391 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7391 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7378 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7375 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7375 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7355 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7347 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7347 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7326 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7325 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7305 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7305 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7257 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.725 |
Intermediate Similarity |
NPD6386 |
Approved |
0.725 |
Intermediate Similarity |
NPD6385 |
Approved |
0.7248 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD7966 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7246 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7239 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7237 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.723 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7229 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7225 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD5353 |
Approved |
0.7215 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7212 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.72 |
Intermediate Similarity |
NPD447 |
Suspended |
0.72 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7188 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7169 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7133 |
Intermediate Similarity |
NPD826 |
Approved |
0.7133 |
Intermediate Similarity |
NPD825 |
Approved |
0.7124 |
Intermediate Similarity |
NPD9570 |
Approved |
0.7122 |
Intermediate Similarity |
NPD2629 |
Approved |
0.7111 |
Intermediate Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.7108 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7097 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7092 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7089 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7089 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7059 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7051 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7051 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7048 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7047 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7034 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7024 |
Intermediate Similarity |
NPD5242 |
Approved |
0.702 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7007 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7007 |
Intermediate Similarity |
NPD3022 |
Approved |
0.6981 |
Remote Similarity |
NPD2532 |
Approved |
0.6981 |
Remote Similarity |
NPD3688 |
Clinical (unspecified phase) |
0.6981 |
Remote Similarity |
NPD2533 |
Approved |
0.6981 |
Remote Similarity |
NPD2534 |
Approved |
0.6981 |
Remote Similarity |
NPD3146 |
Approved |
0.698 |
Remote Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.6974 |
Remote Similarity |
NPD555 |
Phase 2 |
0.6948 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6943 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6943 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6936 |
Remote Similarity |
NPD6559 |
Discontinued |
0.6933 |
Remote Similarity |
NPD7411 |
Suspended |
0.6928 |
Remote Similarity |
NPD6653 |
Approved |
0.6923 |
Remote Similarity |
NPD1549 |
Phase 2 |
0.6918 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6913 |
Remote Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.6908 |
Remote Similarity |
NPD1240 |
Approved |
0.6906 |
Remote Similarity |
NPD228 |
Approved |
0.6903 |
Remote Similarity |
NPD1551 |
Phase 2 |
0.6901 |
Remote Similarity |
NPD9493 |
Approved |
0.6899 |
Remote Similarity |
NPD3887 |
Approved |
0.6899 |
Remote Similarity |
NPD2354 |
Approved |
0.6889 |
Remote Similarity |
NPD6535 |
Approved |
0.6889 |
Remote Similarity |
NPD6534 |
Approved |
0.6886 |
Remote Similarity |
NPD919 |
Approved |
0.6884 |
Remote Similarity |
NPD2067 |
Discontinued |
0.6875 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.6865 |
Remote Similarity |
NPD7435 |
Discontinued |
0.6863 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6861 |
Remote Similarity |
NPD1358 |
Approved |
0.6859 |
Remote Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.6859 |
Remote Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6849 |
Remote Similarity |
NPD1535 |
Discovery |
0.6846 |
Remote Similarity |
NPD258 |
Approved |
0.6846 |
Remote Similarity |
NPD257 |
Approved |
0.6842 |
Remote Similarity |
NPD6663 |
Approved |
0.6842 |
Remote Similarity |
NPD259 |
Phase 1 |
0.6839 |
Remote Similarity |
NPD7038 |
Approved |
0.6839 |
Remote Similarity |
NPD7039 |
Approved |
0.6839 |
Remote Similarity |
NPD7240 |
Approved |
0.6835 |
Remote Similarity |
NPD3750 |
Approved |
0.6832 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6828 |
Remote Similarity |
NPD1778 |
Approved |
0.6828 |
Remote Similarity |
NPD17 |
Approved |
0.6824 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6818 |
Remote Similarity |
NPD1607 |
Approved |
0.6815 |
Remote Similarity |
NPD4534 |
Discontinued |
0.6805 |
Remote Similarity |
NPD1247 |
Approved |
0.6803 |
Remote Similarity |
NPD1481 |
Phase 2 |
0.68 |
Remote Similarity |
NPD5736 |
Approved |
0.6795 |
Remote Similarity |
NPD2438 |
Suspended |
0.6795 |
Remote Similarity |
NPD2796 |
Approved |
0.6793 |
Remote Similarity |
NPD6778 |
Approved |
0.6793 |
Remote Similarity |
NPD6782 |
Approved |
0.6793 |
Remote Similarity |
NPD6779 |
Approved |
0.6793 |
Remote Similarity |
NPD6776 |
Approved |
0.6793 |
Remote Similarity |
NPD6781 |
Approved |
0.6793 |
Remote Similarity |
NPD6777 |
Approved |
0.6793 |
Remote Similarity |
NPD6780 |
Approved |
0.6781 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6776 |
Remote Similarity |
NPD7699 |
Phase 2 |
0.6776 |
Remote Similarity |
NPD7700 |
Phase 2 |
0.6774 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6772 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.677 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.6761 |
Remote Similarity |
NPD690 |
Clinical (unspecified phase) |
0.6757 |
Remote Similarity |
NPD2983 |
Phase 2 |
0.6757 |
Remote Similarity |
NPD2982 |
Phase 2 |
0.6752 |
Remote Similarity |
NPD5763 |
Approved |
0.6752 |
Remote Similarity |
NPD5762 |
Approved |
0.6748 |
Remote Similarity |
NPD3687 |
Approved |
0.6748 |
Remote Similarity |
NPD3686 |
Approved |
0.6747 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6743 |
Remote Similarity |
NPD8368 |
Discontinued |
0.6738 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.6738 |
Remote Similarity |
NPD8319 |
Approved |
0.6735 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6733 |
Remote Similarity |
NPD6007 |
Clinical (unspecified phase) |
0.6733 |
Remote Similarity |
NPD5647 |
Approved |
0.6715 |
Remote Similarity |
NPD5048 |
Discontinued |
0.6713 |
Remote Similarity |
NPD4198 |
Discontinued |
0.6711 |
Remote Similarity |
NPD3225 |
Approved |
0.6709 |
Remote Similarity |
NPD5958 |
Discontinued |
0.6709 |
Remote Similarity |
NPD2424 |
Discontinued |
0.6707 |
Remote Similarity |
NPD3226 |
Approved |
0.6707 |
Remote Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.669 |
Remote Similarity |
NPD1894 |
Discontinued |
0.6689 |
Remote Similarity |
NPD9569 |
Approved |
0.6689 |
Remote Similarity |
NPD2981 |
Phase 2 |
0.6689 |
Remote Similarity |
NPD3018 |
Phase 2 |
0.6688 |
Remote Similarity |
NPD6100 |
Approved |
0.6688 |
Remote Similarity |
NPD6099 |
Approved |
0.6686 |
Remote Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD8312 |
Approved |
0.6667 |
Remote Similarity |
NPD1203 |
Approved |
0.6667
|
Remote Similarity |
NPD2797 |
Approved |